Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-0171 in infants and toddlers with RSV LRTI
NCT02309320Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2014
- Primary completion
- Feb 2016
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 2 trial of gontivimab in respiratory syncytial virus infection (RSV), sponsored by Sanofi. Started Dec 2014; status: completed.
02
Drugs
gontivimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02309320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02309320.